Sessarego M, Frassoni F, Defferrari R, Bacigalupo A, Fugazza G, Mareni C, Bruzzone R, Dejana A, Ajmar F
Dipartimento Medicina Interna, University of Genoa, Italy.
Cancer Genet Cytogenet. 1991 Nov;57(1):69-78. doi: 10.1016/0165-4608(91)90191-v.
Sixty-eight patients affected by Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) underwent allogeneic bone marrow transplantation (BMT) and were successfully studied from a cytogenetic point of view, before and after the BMT. Nineteen had evidence of cytogenetic and clinical relapse. Cytogenetic analyses of 14 patients who, after the relapse, showed progression to the accelerated or blastic phase of the disease, are presented. Five of these cases had only the Ph chromosome without karyotype evolution; in one case Ph duplication without other anomalies was detected, while in the remaining eight cases cytogenetic analysis showed apparently random clonal structural abnormalities (translocations, inversions, deletions, and marker formations). Therefore, the classical "non-random" abnormalities (+8, i(17q), +Ph, +19, +21) were not as common as in conventionally treated Ph+ CML. From our data, karyotype evolution during advanced phases in Ph+ CML patients after BMT differs from the evolution seen in conventionally treated patients, by the presence of numerous structural unusual abnormalities, possibly related to radiochemotherapy conditioning to BMT. Therefore, BMT treatment is not always able to eradicate the Ph+ clone but can reduce the incidence of the formation and/or expansion of Ph+ clones with additional non-random abnormalities.
68例费城染色体(Ph)阳性慢性粒细胞白血病(CML)患者接受了异基因骨髓移植(BMT),并在BMT前后从细胞遗传学角度进行了成功研究。19例有细胞遗传学和临床复发的证据。本文呈现了14例患者复发后疾病进展至加速期或急变期的细胞遗传学分析。其中5例仅有Ph染色体,无核型演变;1例检测到Ph重复,无其他异常,而其余8例细胞遗传学分析显示明显随机的克隆性结构异常(易位、倒位、缺失和标记形成)。因此,经典的“非随机”异常(+8、i(17q)、+Ph、+19、+21)不如传统治疗的Ph+CML常见。根据我们的数据,BMT后Ph+CML患者晚期的核型演变与传统治疗患者的演变不同,存在许多结构异常,可能与BMT的放化疗预处理有关。因此,BMT治疗并不总是能够根除Ph+克隆,但可以降低具有额外非随机异常的Ph+克隆形成和/或扩增的发生率。